Meet with... Poliwogg
StartX , 2627 Hanover Street , Palo Alto , CA 94304
November 20, 2014 from 11:30 AM to 13:30 PM (PDT)
$10 - $35
The rise of alternative funding has forever changed the way money is being raised, and Poliwogg is capitalizing on that shift to help life science startups and transform healthcare investing. Poliwogg's unique crowd equity online investment platform enables individual, accredited investors to invest directly in private life science, biotechnology, and healthcare companies. Poliwogg is interested in innovative early stage companies across all areas of healthcare and life sciences seeking to raise between $1m and $10m, including biopharmaceuticals, diagnostics, devices, health IT, and big data. Headquartered in New York City, Poliwogg also has a presence in Boston, Southern California, and the Bay Area.
Representatives from Poliwogg will be in attendance to give an overview presentation on the organization's key areas of interest and best practices when seeking funding. Attendees will also get the latest scoop on Poliwogg's "Innovation Funds," a new series of publicly registered venture funds with investments ranging from $500k to $5m. Following the presentation, don't miss this opportunity to introduce yourself to Poliwogg during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with David Jaffin and Samuel Wertheimer from Poliwogg will provide a forum to discuss your company.
Don't miss the opportunity to meet one-on-one with Poliwogg!
10:30am | Registration and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
12:30-4:00pm | One-on-one Meetings*
*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends has closed on October 17th.
Poliwogg Participating Representatives:
David W. Jaffin | Chief Financial Officer, Poliwogg read bio»
Samuel Wertheimer, Ph.D. | Chief Investment Officer, Poliwogg read bio»
Poliwogg is a financial services firm dedicated to expanding and transforming healthcare investing. Poliwogg provides opportunities for accredited investors to invest in early stage companies in healthcare and the life sciences through its online investment platform and is launching publicly registered venture funds focused by healthcare subsector. Poliwogg is interested in innovative early stage companies across all areas of healthcare and life sciences, including biopharmaceuticals, diagnostics, devices, health IT, and big data. Headquartered in New York City, Poliwogg also has a presence in Boston, Southern California, and the Bay Area.
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until November 19.
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period has closed. Your application will be reviewed and you will be notified of acceptance by November 4, 2014. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
2627 Hanover Street
Palo Alto, CA
Poliwogg Representatives' Biographies:
David W. Jaffin | Chief Financial Officer, Poliwogg
Mr. Jaffin has extensive experience both in public and private companies, fund management, and in private equity investing. From its founding in 2005 until its sale in 2010, he was Chief Operating Officer of XShares Advisors LLC. He was the first partner to join XShares after its founding and helped raise the start-up capital and the first institutional round of financing. He was responsible for the company's and its fund operations, including the launch of three ETF series: HealthShares, AdelanteShares, and TDX Independence Funds, plus a related '33 Act fund specializing in carbon credits, AirShares; he also worked closely with the company's Chief Compliance Officer on regulatory issues. He had primary interface responsibilities with the company's suppliers and partners, including the Bank of New York, Kellogg Capital, Goldman Sachs, NYSE, and Paul Hastings.
After XShares was sold to Deutsche Bank in 2010 Mr. Jaffin became a consultant to Deutsche Bank. His responsibilities included transition/onboarding issues and development of compliance and other infrastructure in preparation for the bank's launch of its own exchange traded funds.
From 1998 to 2005, he was first Vice President and then President and CEO of Technical Coatings Laboratory, a manufacturer of specialty paints and coatings in Avon, CT. Mr. Jaffin arranged for the financing to buy out the original owner, and increased reve- nues, operating profitability, and production capacity. Its major customers included Hallmark Cards, Dunlop-Maxfli, and Acushnet (Titleist).
From 1992 to 1998 he was CFO of HoloPak Technologies, Inc., a manufacturer of specialty coatings, which was traded on NASDAQ. Previously, he also was a Vice President at Bradford Ventures Ltd., a leveraged buyout firm affiliated with Bessemer Securities Corporation. Earlier he worked as an auditor for Arthur Andersen & Co.
Mr. Jaffin received a BA, cum laude, from Harvard College, and an MBA from New York University. He is a Certified Public Accountant in the State of New York and holds Series 7, 24, 27, 63, 79 and 99 Licenses from FINRA. He is a resident of Woodbury, Connecticut.
Samuel Wertheimer, Ph.D. | Chief Investment Officer, Poliwogg
Dr. Wertheimer is Chief Investment Officer at Poliwogg and has over two decades of experience as an investor in the healthcare and life sciences sectors, specializing in due diligence and investment oversight.
Prior to Poliwogg, Dr. Wertheimer spent ten years as an equity partner in OrbiMed Advisors, LLC, the world's largest healthcare-dedicated investment firm, with approximately $5 billion under management. At Orbimed, Dr. Wertheimer was responsible for the management of biotechnology/medical technology focusing on venture capital funds, including the sourcing, due diligence, negotiation and management of investments. He had ten primary investments, five successful exits and brought two new products to market. He was also a Member of the OrbiMed Private Equity Investment Oversight Committee. During his tenure, he raised four venture capital funds totaling $1.5 billion in committed capital. The most recent fund, Caduceus Private Investments IV, raised $550 million and closed February 2010. He was a Member of the Board of Directors of invested companies and assisted in the management of a $5 billion long/short healthcare portfolio in the pharmaceutical and biotechnology sectors.
Dr. Wertheimer also worked at Paramount Capital, LLC, where he identified and conducted due diligence on biotechnology and pharmaceutical assets for license to various companies. Earlier, he served as a patent agent, and a research scientist at Memorial Sloan Kettering Cancer Center (MSKCC). While at MSKCC, he had ten peer-reviewed scientific publications and two patent applications.
Dr. Wertheimer received his Doctor of Philosophy degree from New York University, his Master of Public Health, with Honors from Yale University and his Bachelor of Arts from the Johns Hopkins University. He holds a Series 7 license.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, Correlation Ventures, Breakout Labs, New Enterprise Associates, and Thomas McNerney & Partners.